Evidence map›Paper›PMID 39434891›Full record

ArticleJHEP reports : innovation in hepatology2024

Albumin reprograms the B cell transcriptional landscape and improves neutrophil antimicrobial function in patients with decompensated cirrhosis.

Joan Clària, Ferran Aguilar, Juan-José Lozano, Laura Jiménez-Gracia, Juan C Nieto, Berta Romero-Grimaldo, Xavi Marcos-Fa, Emma Giarracco, Emmanuel Weiss, Jonel Trebicka and 18 more

Abstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Joan ClàriaEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Ferran AguilarEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Juan-José LozanoCIBER of Hepatic and Digestive Diseases (CIBERehd); Barcelona, Spain.
Laura Jiménez-GraciaUniversitat de Barcelona, Barcelona, Spain.
Juan C NietoUniversitat de Barcelona, Barcelona, Spain.
Berta Romero-GrimaldoEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Xavi Marcos-FaTranslational Clinical Research Program, Institute "Hospital del Mar" for Medical Investigations (IMIM), Barcelona, Spain.
Emma GiarraccoTranslational Clinical Research Program, Institute "Hospital del Mar" for Medical Investigations (IMIM), Barcelona, Spain.
Emmanuel WeissEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Jonel TrebickaEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Inmaculada HernàndezUniversitat de Barcelona, Barcelona, Spain.
Javier FernandezEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Mireia CasullerasEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Cristina López-VicarioEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Sinan MuldurCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital, Shriners Burns Hospital, Harvard Medical School, Boston, MA, USA.
Alex HopkeCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital, Shriners Burns Hospital, Harvard Medical School, Boston, MA, USA.
Alexandru VlageaHospital Clínic-IDIBAPS, Barcelona, Spain.
Ana M AransayCIBER of Hepatic and Digestive Diseases (CIBERehd); Barcelona, Spain.
Domenica MarcheseUniversitat de Barcelona, Barcelona, Spain.
Mauro BernardiDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Rajiv JalanEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Paolo AngeliEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Giuliana MagriImmunology Unit, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Andrea CeruttiTranslational Clinical Research Program, Institute "Hospital del Mar" for Medical Investigations (IMIM), Barcelona, Spain.
Daniel IrimiaCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital, Shriners Burns Hospital, Harvard Medical School, Boston, MA, USA.
Holger HeynUniversitat de Barcelona, Barcelona, Spain.
Vicente ArroyoEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.
Richard MoreauEuropean Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)-CLIF Consortium, and Grifols Chair, Barcelona, Spain.

Funding

In vivo Monitoring of Neutrophil Function in Patients after Stem Cell TransplantR01AI176658 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel Irimia, Charles P. Lin · 2023 to 2026
$3.2M
NIAID NIH HHS R01 AI176658
6 · The paper itself

Abstract

Background & Aims: Patients with acutely decompensated (AD) cirrhosis are immunocompromised and particularly susceptible to infections. This study investigated the immunomodulatory actions of albumin by which this protein may lower the incidence of infections. Methods: Blood immunophenotyping was performed in 11 patients with AD cirrhosis and 10 healthy volunteers (HV). Bulk and single-cell RNA sequencing (scRNA-seq) and flow cytometry were performed in peripheral blood mononuclear cells (PBMCs) from 20 patients with AD cirrhosis and 34 HV exposed to albumin. Albumin's effects on degranulation, phagocytosis, chemotaxis, and swarming of neutrophils from six patients with AD cirrhosis and nine HV were assessed by measuring myeloperoxidase enzymatic activity, the engulfment of fluorescent-labeled Results: Compared with HV, patients with AD cirrhosis showed severe lymphopenia and defective neutrophil antimicrobial function. Bulk and scRNA-seq analyses revealed significantly (false discovery rate [FDR] <0.05) increased signatures related to B cells, myeloid cells, and CD4 Conclusions: The finding that albumin promotes the transcriptional reprogramming and expansion of the B cell compartment and improves neutrophil antimicrobial functions indicates mechanisms that may lower the incidence of infections in patients with severe AD cirrhosis receiving albumin therapy. Impact and implications: Patients with acutely decompensated cirrhosis receiving albumin as treatment have a lower incidence of infections. The reason for this protection is currently unknown, but the present study provides data that support the ability of albumin to boost the antimicrobial functions of immune cells in these patients. Moreover, these findings encourage the design of controlled clinical studies specifically aimed at investigating the effects of albumin administration on the immune system.

Indexed as

Gene expressionImmunosuppressionInflammationMultiorgan failure

Identifiers

PMID39434891
PMCPMC11490805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.